IMNM Stock — Immunome Inc.: Cash, EV, Pipeline

What they do

We are a biotechnology company committed to the development of first-in-class and best-in-class targeted oncology therapies. Our goal is to establish a broad portfolio of differentiated clinical assets to improve the lives of cancer patients. Key to that strategy is our deep expertise in the discovery, design, development, manufacturing, and ultimately commercialization of antibody-drug conjugates and other oncology therapeutics.

Source: 10-K FY2025 via SEC EDGAR

Share price

$18.71

Market cap

$2,207.8M

Cash

$520.0M

Enterprise value

$1,687.8M

Balance sheet

Cash	$520.0M
Debt	$0.0M
Net cash	$520.0M
Enterprise value	$1,687.8M
Basic shares	113.6M shares
Fully diluted shares	133.1M shares
Fully diluted market cap	$2,489.5M
Cash per share	$4.58
Quarterly burn	$61.7M
Cash runway	8.4 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

113.6M

Pre-funded warrants

0.0M

Options

16.9M

RSUs

0.0M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

2.6M

FDSO

133.1M

Cap table as of 2026-06-30.

Price history

Loading IMNM daily closes…

Loading price history…

Next catalyst

IM-1021 · Est. Nov 7, 2026 · guidance midpoint · guided Now

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 7, 2026 Now guidance midpoint	IM-1021 Phase 1 in B-cell lymphoma	Phase 1	B-cell lymphoma	2026
GUIDEDApr 28, 2027 in 6 mo	varegacestat (AL102) Phase 3 RINGSIDE in desmoid tumors	Phase 3	desmoid tumors	April 28, 2027 (PDUFA)
Jun 12 - Jul 24 in 19 mo	IM-1021	Phase 1	Solid Malignancies; Hematologic Malignancies	—
Feb 12 - Mar 26 in 28 mo	IM-1617	Phase 1	Colorectal Cancer; Non-Small Cell Lung Cancer; Breast Cancer	—
Jan 12 - Feb 23 in 39 mo	177Lu-IM-3050	Early Phase 1	Solid Malignancies	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Varegacestat

Phase 3 · Active Modality: oral gamma secretase inhibitor

Aliases AL102

Target gamma secretase

Partnerships Ayala Pharmaceuticals (asset acquisition, March 2024); Bristol-Myers Squibb (license)

Indications

desmoid tumors (Phase 3)

Catalysts

— April 28, 2027
— end of 2026

Status note NDA submitted April 2026 and accepted July 2026; Phase 3 RINGSIDE Part B completed; no discontinuation disclosed.

IM-1021

Phase 1 · Active Modality: antibody-drug conjugate (ROR1, HC74 TOP1 inhibitor payload)

Target ROR1

Indications

solid tumors (Phase 1)
B-cell lymphoma (Phase 1)

Catalysts

— 2026

Status note Phase 1 ongoing; no discontinuation disclosed.

IM-1617

Phase 1 · Active Modality: antibody-drug conjugate

Indications

solid tumors (colorectal, NSCLC, breast, ovarian) (Phase 1)

Status note First participant dosed June 2026; target is an undisclosed receptor tyrosine kinase; no discontinuation disclosed.

IM-3050

Phase 1 · Active Modality: FAP-targeted lutetium-177 radioligand therapy

Target FAP

Indications

FAP-expressing solid tumors (Phase 1)

Status note First participant dosed July 2026; no discontinuation disclosed.

IM-1340

Preclinical · Active Modality: antibody-drug conjugate

Indications

neuroendocrine tumors (Preclinical)
lung and prostate carcinomas (Preclinical)

Catalysts

— mid-2026

Status note IND-enabling work ongoing; IND submission expected mid-2026 per filing; no discontinuation disclosed.

IM-1335

Preclinical · Active Modality: antibody-drug conjugate

Indications

solid tumors (Preclinical)

Catalysts

— late 2026

Status note IND-enabling work ongoing; shares target with a discontinued competitor ADC; no discontinuation disclosed.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	AL102
Lead indication	Desmoid
Lead phase	Phase 3
Active trials	5

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT04871282	Phase 3	Active, not recruiting	Sponsor	IMNM	—	Desmoid; Desmoid Tumor	April 28, 2027 (PDUFA)
NCT06823167	Phase 1	Recruiting	Sponsor	IMNM	—	Solid Malignancies; Hematologic Malignancies	—
NCT07578571	Phase 1	Recruiting	Sponsor	IMNM	—	Colorectal Cancer; Non-Small Cell Lung Cancer; Breast Cancer	—
NCT07610005	Phase 1	Recruiting	Sponsor	IMNM	—	Healthy	—
NCT07505771	Early Phase 1	Recruiting	Sponsor	IMNM	—	Solid Malignancies	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Immunome, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Ikarian Capital	60,000	+60,000	0.21%	2026-08-14
Baker Bros. Advisors	55,306	+55,306	0.01%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

IMNM — Immunome Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

IMNM — Immunome Inc.